AZD8055
| Title | Journal |
|---|---|
| Prevention of BMS-777607-induced polyploidy/senescence by mTOR inhibitor AZD8055 sensitizes breast cancer cells to cytotoxic chemotherapeutics. | Molecular oncology 20140501 |
| mTOR/p70S6K signaling distinguishes routine, maintenance-level autophagy from autophagic cell death during influenza A infection. | Virology 20140301 |
| PI3Kδ inhibition augments the efficacy of rapamycin in suppressing proliferation of Epstein-Barr virus (EBV)+ B cell lymphomas. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20130801 |
| Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014. | Bioorganic & medicinal chemistry letters 20130301 |
| Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma. | British journal of cancer 20120925 |
| The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. | Leukemia 20120601 |
| Stable isotope-labelling analysis of the impact of inhibition of the mammalian target of rapamycin on protein synthesis. | The Biochemical journal 20120515 |
| TOR signaling and rapamycin influence longevity by regulating SKN-1/Nrf and DAF-16/FoxO. | Cell metabolism 20120502 |
| Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055). | Cancer research 20120401 |
| Mammalian target of rapamycin (mTOR) inhibition reduces cerebral vasospasm following a subarachnoid hemorrhage injury in canines. | Experimental neurology 20120201 |
| Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype. | PloS one 20120101 |
| Inhibition of mTOR kinase by AZD8055 can antagonize chemotherapy-induced cell death through autophagy induction and down-regulation of p62/sequestosome 1. | The Journal of biological chemistry 20111118 |
| Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition. | Cancer research 20110801 |
| mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. | Cancer discovery 20110617 |
| mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment. | Cancer research 20110615 |
| Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055. | Biochemical Society transactions 20110401 |
| Effect of PI3K- and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKB1-deficient mice. | British journal of cancer 20110329 |
| Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer. | Journal of medicinal chemistry 20110310 |
| Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment. | Bioorganic & medicinal chemistry letters 20100801 |
| Mammalian autophagy: core molecular machinery and signaling regulation. | Current opinion in cell biology 20100401 |
| AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. | Cancer research 20100101 |
| Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. | Nature 20090716 |
| Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. | Current biology : CB 20040727 |
| Regulation of longevity and stress resistance by Sch9 in yeast. | Science (New York, N.Y.) 20010413 |